{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:07:06Z","timestamp":1791900426226,"version":"4.3.4"},"reference-count":133,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010621","name":"Medical University of Lublin","doi-asserted-by":"crossref","award":["DS 411\/2022"],"award-info":[{"award-number":["DS 411\/2022"]}],"id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Acute myeloid leukemia (AML) is a disease that mainly affects elderly patients who are more often unfit for intensive chemotherapy (median age of diagnosis is 68). The regimens, including venetoclax, a highly specific BCL-2 (B-cell lymphoma-2) inhibitor, are a common alternative because of their safer profile and fewer side effects. However, the resistance phenomenon of leukemic cells necessitates the search for drugs that would help to overcome the resistance and improve treatment outcomes. One of the resistance mechanisms takes place through the upregulation of MCL-1 and BCL-XL, preventing BAX\/BAK-driven MOMP (mitochondrial outer membrane permeabilization), thus stopping the apoptosis process. Possible partners for BCL-2 inhibitors may include inhibitors from the FLT3i (FMS-like tyrosine kinase-3 inhibitor) group. They resensitize cancer cells through the downregulation of MCL-1 expression in the FLT3 mutated cells, resulting in the stronger efficacy of BCL-2 inhibitors. Also, they provide an additional pathway for targeting the clonal cell. Both preclinical and clinical data suggest that the combination might show a synergistic effect and improve patients\u2019 outcomes. The aim of this review is to determine whether the combination of venetoclax and FLT3 inhibitors can impact the therapeutic approaches and what other agents they can be combined with.<\/jats:p>","DOI":"10.3390\/ijms242115849","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T03:29:33Z","timestamp":1698809373000},"page":"15849","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens"],"prefix":"10.3390","volume":"24","author":[{"given":"Szymon","family":"Milnerowicz","sequence":"first","affiliation":[{"name":"Student Scientific Society, Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Milnerowicz","sequence":"additional","affiliation":[{"name":"Student Scientific Society, Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Skowera","sequence":"additional","affiliation":[{"name":"Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Stelmach","sequence":"additional","affiliation":[{"name":"Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8760-0775","authenticated-orcid":false,"given":"Monika","family":"Lejman","sequence":"additional","affiliation":[{"name":"Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,31]]},"reference":[{"key":"ref_1","unstructured":"Vakiti, A., and Mewawalla, P. (2023). Acute Myeloid Leukemia. StatPearls, StatPearls Publishing."},{"key":"ref_2","first-page":"17","article-title":"Cancer Statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","unstructured":"(2023, August 01). SEER Cancer Stat Facts: Acute Myeloid Leukemia, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13045-020-00908-z","article-title":"The Global Burden and Attributable Risk Factor Analysis of Acute Myeloid Leukemia in 195 Countries and Territories from 1990 to 2017: Estimates Based on the Global Burden of Disease Study 2017","volume":"13","author":"Yi","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.7150\/jca.32326","article-title":"The Epidemiological Trend of Acute Myeloid Leukemia in Childhood: A Population-Based Analysis","volume":"10","author":"Chen","year":"2019","journal-title":"J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Reinhardt, D., Antoniou, E., and Waack, K. (2022). Pediatric Acute Myeloid Leukemia\u2014Past, Present, and Future. J. Clin. Med., 11.","DOI":"10.3390\/jcm11030504"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 Family Proteins: Changing Partners in the Dance towards Death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Hafezi, S., and Rahmani, M. (2021). Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives. Cancers, 13.","DOI":"10.3390\/cancers13061292"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Moldoveanu, T. (2023). Apoptotic Mitochondrial Poration by a Growing List of Pore-forming BCL-2 Family Proteins. BioEssays, 45.","DOI":"10.1002\/bies.202200221"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Pfeffer, C., and Singh, A. (2018). Apoptosis: A Target for Anticancer Therapy. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020448"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood-2018-02-791350","article-title":"The Rise of Apoptosis: Targeting Apoptosis in Hematologic Malignancies","volume":"132","author":"Valentin","year":"2018","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","article-title":"BCL-2 Inhibition in AML: An Unexpected Bonus?","volume":"132","author":"Konopleva","year":"2018","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Totiger, T.M., Ghoshal, A., Zabroski, J., Sondhi, A., Bucha, S., Jahn, J., Feng, Y., and Taylor, J. (2023). Targeted Therapy Development in Acute Myeloid Leukemia. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020641"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"564108","DOI":"10.3389\/fphar.2020.564108","article-title":"Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent","volume":"11","author":"Liew","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a Potent and Selective BCL-2 Inhibitor, Achieves Antitumor Activity While Sparing Platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From Basic Apoptosis Discoveries to Advanced Selective BCL-2 Family Inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ccr.2007.07.001","article-title":"BH3 Profiling Identifies Three Distinct Classes of Apoptotic Blocks to Predict Response to ABT-737 and Conventional Chemotherapeutic Agents","volume":"12","author":"Deng","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.1206727","article-title":"Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy","volume":"334","author":"Chonghaile","year":"2011","journal-title":"Science"},{"key":"ref_19","unstructured":"(2023, August 01). FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute Myeloid Leukemia, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-venetoclax-combination-untreated-acute-myeloid-leukemia."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"E299","DOI":"10.1002\/ajh.26600","article-title":"Timing of Response with Venetoclax Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia","volume":"97","author":"Jonas","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/10428194.2023.2197090","article-title":"Real-World Outcomes of Frontline Venetoclax-Based Therapy in Older Adults with Acute Myeloid Leukemia: An Analysis Utilizing EHR Data","volume":"64","author":"Hoff","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","article-title":"Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Na\u00efve Acute Myeloid Leukemia","volume":"28","author":"Konopleva","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1080\/14656566.2017.1391216","article-title":"Cytarabine and Daunorubicin for the Treatment of Acute Myeloid Leukemia","volume":"18","author":"Murphy","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1016\/S2352-3026(22)00076-X","article-title":"Venetoclax Combined with Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia: A Post-Hoc, Propensity Score-Matched, Cohort Study","volume":"9","author":"Lachowiez","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3 + 7 Daunorubicin and Cytarabine Chemotherapy as First-Line Treatment for Adults with Acute Myeloid Leukaemia: A Multicentre, Single-Arm, Phase 2 Trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40164-023-00409-y","article-title":"Venetoclax Combined with Daunorubicin and Cytarabine (2 + 6) as Induction Treatment in Adults with Newly Diagnosed Acute Myeloid Leukemia: A Phase 2, Multicenter, Single-Arm Trial","volume":"12","author":"Suo","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"204062072210939","DOI":"10.1177\/20406207221093964","article-title":"Advancing the Standard: Venetoclax Combined with Intensive Induction and Consolidation Therapy for Acute Myeloid Leukemia","volume":"13","author":"Lachowiez","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1182\/blood-2021-150457","article-title":"Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia","volume":"138","author":"Lachowiez","year":"2021","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s00277-022-04883-y","article-title":"Venetoclax in Combination with FLAG-IDA-Based Protocol for Patients with Acute Myeloid Leukemia: A Real-World Analysis","volume":"101","author":"Wolach","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/16078454.2020.1843752","article-title":"The Efficacy and Adverse Events of Venetoclax in Combination with Hypomethylating Agents Treatment for Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis","volume":"25","author":"Guo","year":"2020","journal-title":"Hematology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in Combination with Cytarabine with or without Idarubicin in Children with Relapsed or Refractory Acute Myeloid Leukaemia: A Phase 1, Dose-Escalation Study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Trabal, A., Gibson, A., He, J., McCall, D., Roth, M., Nu\u00f1ez, C., Garcia, M., Buzbee, M., Toepfer, L., and Bidikian, A. (2023). Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience. Cancers, 15.","DOI":"10.3390\/cancers15071983"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.stem.2020.07.021","article-title":"Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells","volume":"27","author":"Jones","year":"2020","journal-title":"Cell Stem Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty Acid Metabolism Underlies Venetoclax Resistance in Acute Myeloid Leukemia Stem Cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1005659","DOI":"10.3389\/fonc.2022.1005659","article-title":"Mechanisms of Venetoclax Resistance and Solutions","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_40","first-page":"125","article-title":"Resistance to Venetoclax and Hypomethylating Agents in Acute Myeloid Leukemia","volume":"4","author":"Saliba","year":"2020","journal-title":"Cancer Drug Resist."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40164-022-00283-0","article-title":"Progress in Understanding the Mechanisms of Resistance to BCL-2 Inhibitors","volume":"11","author":"Xu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine\/Venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"27696","DOI":"10.1038\/srep27696","article-title":"Targeting MCL-1\/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Fedorov, K., Maiti, A., and Konopleva, M. (2023). Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions. Cancers, 15.","DOI":"10.3390\/cancers15082312"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7150\/ijms.1.101","article-title":"Tyrosine Kinase\u2014Role and Significance in Cancer","volume":"1","author":"Paul","year":"2004","journal-title":"Int. J. Med. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Friedman, R. (2022). The Molecular Mechanisms behind Activation of FLT3 in Acute Myeloid Leukemia and Resistance to Therapy by Selective Inhibitors. Biochim. Biophys. Acta BBA Rev. Cancer, 1877.","DOI":"10.1016\/j.bbcan.2021.188666"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.5045\/br.2022.2022017","article-title":"FLT3 Mutations in Acute Myeloid Leukemia: A Review Focusing on Clinically Applicable Drugs","volume":"57","author":"Ahn","year":"2022","journal-title":"Blood Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"100905","DOI":"10.1016\/j.blre.2021.100905","article-title":"A Review of FLT3 Inhibitors in Acute Myeloid Leukemia","volume":"52","author":"Zhao","year":"2022","journal-title":"Blood Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The Genetics of Myelodysplastic Syndrome: From Clonal Haematopoiesis to Secondary Leukaemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and Management of AML in Adults: 2022 Recommendations from an International Expert Panel on Behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed\/Refractory Acute Myeloid Leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 Mutated Acute Myeloid Leukemia: 2021 Treatment Algorithm","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1182\/blood-2010-12-327072","article-title":"The FLT3ITD MRNA Level Has a High Prognostic Impact in NPM1 Mutated, but Not in NPM1 Unmutated, AML with a Normal Karyotype","volume":"119","author":"Schneider","year":"2012","journal-title":"Blood"},{"key":"ref_55","unstructured":"Enna, S.J., and Bylund, D.B. (2007). Tyrosine Kinase Inhibitors. xPharm: The Comprehensive Pharmacology Reference, Elsevier."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood-2013-01-478172","article-title":"FLT3 Inhibitor-Induced Neutrophilic Dermatosis","volume":"122","author":"Fathi","year":"2013","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Ghelli Luserna Di Ror\u00e0, A., Jandoubi, M., Martinelli, G., and Simonetti, G. (2023). Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon. Molecules, 28.","DOI":"10.3390\/molecules28031224"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 Mutations in AML: Review of Current Knowledge and Evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2643-3230.BCD-20-0143","article-title":"Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors","volume":"2","author":"Alotaibi","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12185-022-03374-0","article-title":"FLT3-Targeted Treatment for Acute Myeloid Leukemia","volume":"116","author":"Arai","year":"2022","journal-title":"Int. J. Hematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"223","DOI":"10.20517\/cdr.2022.130","article-title":"How Acute Myeloid Leukemia (AML) Escapes from FMS-Related Tyrosine Kinase 3 (FLT3) Inhibitors? Still an Overrated Complication?","volume":"6","author":"Perrone","year":"2023","journal-title":"Cancer Drug Resist."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"8817","DOI":"10.2147\/CMAR.S177894","article-title":"Midostaurin in Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection","volume":"11","author":"Abbas","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/2040620717721459","article-title":"Midostaurin: A Novel Therapeutic Agent for Patients with FLT3-Mutated Acute Myeloid Leukemia and Systemic Mastocytosis","volume":"8","author":"Gallogly","year":"2017","journal-title":"Ther. Adv. Hematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/sj.thj.6200165","article-title":"A Novel Treatment Approach for Low Grade Lymphoproliferative Disorders Using PKC412 (CGP41251), an Inhibitor of Protein Kinase C","volume":"3","author":"Virchis","year":"2002","journal-title":"Hematol. J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.bjc.6603331","article-title":"The Multikinase Inhibitor Midostaurin (PKC412A) Lacks Activity in Metastatic Melanoma: A Phase IIA Clinical and Biologic Study","volume":"95","author":"Millward","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1023\/B:DRUG.0000011790.31292.ef","article-title":"A Phase I Trial of Daily Oral 4\u2032-N-Benzoyl-Staurosporine in Combination with Protracted Continuous Infusion 5-Fluorouracil in Patients with Advanced Solid Malignancies","volume":"22","author":"Eder","year":"2004","journal-title":"Investig. New Drugs"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin Approved for FLT3-Mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1038\/s41375-021-01179-4","article-title":"Midostaurin Reduces Relapse in FLT3-Mutant Acute Myeloid Leukemia: The Alliance CALGB 10603\/RATIFY Trial","volume":"35","author":"Larson","year":"2021","journal-title":"Leukemia"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1182\/bloodadvances.2022007223","article-title":"Midostaurin plus Intensive Chemotherapy for Younger and Older Patients with AML and FLT3 Internal Tandem Duplications","volume":"6","author":"Weber","year":"2022","journal-title":"Blood Adv."},{"key":"ref_70","first-page":"1","article-title":"Emerging FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia","volume":"27","author":"Montesinos","year":"2022","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_71","unstructured":"(2012). Midostaurin, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/FPC.0000000000000279","article-title":"PharmGKB Summary: Sorafenib Pathways","volume":"27","author":"Gong","year":"2017","journal-title":"Pharmacogenetics Genom."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib Maintenance in Patients with FLT3-ITD Acute Myeloid Leukaemia Undergoing Allogeneic Haematopoietic Stem-Cell Transplantation: An Open-Label, Multicentre, Randomised Phase 3 Trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3 \u2013Internal Tandem Duplication Mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1200\/JCO.21.01612","article-title":"Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3 \/ITD+ Acute Myeloid Leukemia: A Report From the Children\u2019s Oncology Group Protocol AAML1031","volume":"40","author":"Pollard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Molica, M., Perrone, S., and Rossi, M. (2023). Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3-Mutated AML Patients. J. Clin. Med., 12.","DOI":"10.20944\/preprints202304.1236.v1"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Ezelarab, H.A.A., Ali, T.F.S., Abbas, S.H., Hassan, H.A., and Beshr, E.A.M. (2023). Indole-Based FLT3 Inhibitors and Related Scaffolds as Potential Therapeutic Agents for Acute Myeloid Leukemia. BMC Chem., 17.","DOI":"10.1186\/s13065-023-00981-8"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1182\/blood.2021011583","article-title":"Follow-up of Patients with R\/R FLT3- Mutation\u2013Positive AML Treated with Gilteritinib in the Phase 3 ADMIRAL Trial","volume":"139","author":"Perl","year":"2022","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-022-00677-7","article-title":"Clinical Outcomes in Patients with Relapsed\/Refractory FLT3-Mutated Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib","volume":"12","author":"Perl","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ajh.26447","article-title":"Gilteritinib Clinical Activity in Relapsed\/Refractory FLT3 Mutated ACUTE MYELOID LEUKEMIA Previously Treated with FLT3 Inhibitors","volume":"97","author":"Numan","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.2021014586","article-title":"Phase 3 Trial of Gilteritinib plus Azacitidine vs Azacitidine for Newly Diagnosed FLT3 Mut + AML Ineligible for Intensive Chemotherapy","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1200\/JCO.2013.48.8783","article-title":"Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3\u2013Internal Tandem Duplication Status","volume":"31","author":"Cortes","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus Chemotherapy in Newly Diagnosed Patients with FLT3-Internal-Tandem-Duplication-Positive Acute Myeloid Leukaemia (QuANTUM-First): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"ref_84","unstructured":"(2023, August 01). FDA Approves Quizartinib for Newly Diagnosed Acute Myeloid Leukemia, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-quizartinib-newly-diagnosed-acute-myeloid-leukemia."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2147\/DDDT.S198950","article-title":"Quizartinib (AC220): A Promising Option for Acute Myeloid Leukemia","volume":"13","author":"Zhou","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukaemia (QuANTUM-R): A Multicentre, Randomised, Controlled, Open-Label, Phase 3 Trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","article-title":"Quizartinib, an FLT3 Inhibitor, as Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukaemia: An Open-Label, Multicentre, Single-Arm, Phase 2 Trial","volume":"19","author":"Cortes","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2012.191","article-title":"Mutations of FLT3\/ITD Confer Resistance to Multiple Tyrosine Kinase Inhibitors","volume":"27","author":"Williams","year":"2013","journal-title":"Leukemia"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Eguchi, M., Minami, Y., Kuzume, A., and Chi, S. (2020). Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Biomedicines, 8.","DOI":"10.3390\/biomedicines8080245"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2005-06-2469","article-title":"Clinical Resistance to the Kinase Inhibitor PKC412 in Acute Myeloid Leukemia by Mutation of Asn-676 in the FLT3 Tyrosine Kinase Domain","volume":"107","author":"Heidel","year":"2006","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41467-018-08263-x","article-title":"Clinical Resistance to Crenolanib in Acute Myeloid Leukemia Due to Diverse Molecular Mechanisms","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2016-04-711820","article-title":"Heterogeneous Resistance to Quizartinib in Acute Myeloid Leukemia Revealed by Single-Cell Analysis","volume":"130","author":"Smith","year":"2017","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/leu.2015.165","article-title":"FLT3 D835 Mutations Confer Differential Resistance to Type II FLT3 Inhibitors","volume":"29","author":"Smith","year":"2015","journal-title":"Leukemia"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood.2020007626","article-title":"Clonal Evolution of Acute Myeloid Leukemia with FLT3-ITD Mutation under Treatment with Midostaurin","volume":"137","author":"Schmalbrock","year":"2021","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1038\/onc.2016.41","article-title":"Aberrant Activation of the PI3K\/mTOR Pathway Promotes Resistance to Sorafenib in AML","volume":"35","author":"Lindblad","year":"2016","journal-title":"Oncogene"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1038\/s41375-020-01077-1","article-title":"Activating JAK-Mutations Confer Resistance to FLT3 Kinase Inhibitors in FLT3-ITD Positive AML in Vitro and in Vivo","volume":"35","author":"Rummelt","year":"2021","journal-title":"Leukemia"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Patel, R.K., Weir, M.C., Shen, K., Snyder, D., Cooper, V.S., and Smithgall, T.E. (2019). Expression of Myeloid Src-Family Kinases Is Associated with Poor Prognosis in AML and Influences Flt3-ITD Kinase Inhibitor Acquired Resistance. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0225887"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1182\/blood-2008-12-196055","article-title":"FLT3-ITD up-Regulates MCL-1 to Promote Survival of Stem Cells in Acute Myeloid Leukemia via FLT3-ITD\u2013Specific STAT5 Activation","volume":"114","author":"Yoshimoto","year":"2009","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"15752","DOI":"10.1038\/s41598-018-33982-y","article-title":"Repression of Mcl-1 Expression by the CDC7\/CDK9 Inhibitor PHA-767491 Overcomes Bone Marrow Stroma-Mediated Drug Resistance in AML","volume":"8","author":"Dhami","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/sj.leu.2404776","article-title":"BH3 Mimetic ABT-737 Neutralizes Resistance to FLT3 Inhibitor Treatment Mediated by FLT3-Independent Expression of BCL2 in Primary AML Blasts","volume":"21","author":"Kohl","year":"2007","journal-title":"Leukemia"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1365-2141.2004.05145.x","article-title":"The Expression of P-glycoprotein in AML Cells with FLT3 Internal Tandem Duplications Is Associated with Reduced Apoptosis in Response to FLT3 Inhibitors","volume":"127","author":"Hunter","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2010-01-266742","article-title":"FLT3 Ligand Impedes the Efficacy of FLT3 Inhibitors in Vitro and in Vivo","volume":"117","author":"Sato","year":"2011","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1182\/bloodadvances.2018022921","article-title":"Role of CYP3A4 in Bone Marrow Microenvironment\u2013Mediated Protection of FLT3\/ITD AML from Tyrosine Kinase Inhibitors","volume":"3","author":"Chang","year":"2019","journal-title":"Blood Adv."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"23565","DOI":"10.1038\/s41598-021-03010-7","article-title":"FLT3-ITD Allelic Ratio and HLF Expression Predict FLT3 Inhibitor Efficacy in Adult AML","volume":"11","author":"Kivioja","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","article-title":"Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia","volume":"12","author":"Malani","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/1878-0261.12640","article-title":"CCL5 Mediates Target-kinase Independent Resistance to FLT3 Inhibitors in FLT3-ITD-positive AML","volume":"14","author":"Waldeck","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2147\/OTT.S384293","article-title":"Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches","volume":"15","author":"Tecik","year":"2022","journal-title":"OncoTargets Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/leu.2016.222","article-title":"HOX Gene Expression Predicts Response to BCL-2 Inhibition in Acute Myeloid Leukemia","volume":"31","author":"Kontro","year":"2017","journal-title":"Leukemia"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1038\/s41375-019-0504-y","article-title":"Elevated Expression of S100A8 and S100A9 Correlates with Resistance to the BCL-2 Inhibitor Venetoclax in AML","volume":"33","author":"Karjalainen","year":"2019","journal-title":"Leukemia"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular Patterns of Response and Treatment Failure after Frontline Venetoclax Combinations in Older Patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ccell.2020.10.010","article-title":"Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia","volume":"38","author":"Bhatt","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s43018-020-00165-6","article-title":"A Venetoclax Bench-to-Bedside Story","volume":"2","author":"DiNardo","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","article-title":"Binding of Released Bim to Mcl-1 Is a Mechanism of Intrinsic Resistance to ABT-199 Which Can Be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells","volume":"22","author":"Niu","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax Resistance: Mechanistic Insights and Future Strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug Resist."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","article-title":"Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia","volume":"25","author":"Ma","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-021-00578-4","article-title":"FLT3 Tyrosine Kinase Inhibitors Synergize with BCL-2 Inhibition to Eliminate FLT3\/ITD Acute Leukemia Cells through BIM Activation","volume":"6","author":"Zhu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","article-title":"Venetoclax Combines Synergistically with FLT3 Inhibition to Effectively Target Leukemic Cells in FLT3-ITD+ Acute Myeloid Leukemia Models","volume":"106","author":"Mali","year":"2020","journal-title":"Haematologica"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.2021014241","article-title":"Venetoclax Synergizes with Gilteritinib in FLT3 Wild-Type High-Risk Acute Myeloid Leukemia by Suppressing MCL-1","volume":"140","author":"Janssen","year":"2022","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"101244","DOI":"10.1016\/j.tranon.2021.101244","article-title":"FLT3 Inhibition by Olverembatinib (HQP1351) Downregulates MCL-1 and Synergizes with BCL-2 Inhibitor Lisaftoclax (APG-2575) in Preclinical Models of FLT3-ITD Mutant Acute Myeloid Leukemia","volume":"15","author":"Fang","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ajh.25929","article-title":"Venetoclax and Hypomethylating Agents in FLT3-mutated Acute Myeloid Leukemia","volume":"95","author":"Aldoss","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/ajh.25978","article-title":"Venetoclax and Hypomethylating Agents in Acute Myeloid Leukemia: Mayo Clinic Series on 86 Patients","volume":"95","author":"Morsia","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/bloodadvances.2020003717","article-title":"Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia","volume":"5","author":"Maiti","year":"2021","journal-title":"Blood Adv."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","article-title":"Triplet Therapy with Venetoclax, FLT3 Inhibitor and Decitabine for FLT3-Mutated Acute Myeloid Leukemia","volume":"11","author":"Maiti","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-022-00670-0","article-title":"Hypomethylating Agent and Venetoclax with FLT3 Inhibitor \u201cTriplet\u201d Therapy in Older\/Unfit Patients with FLT3 Mutated AML","volume":"12","author":"Yilmaz","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1200\/JCO.2022.40.16_suppl.7036","article-title":"Quizartinib (QUIZ) with Decitabine (DAC) and Venetoclax (VEN) Is Active in Patients (Pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML): A Phase I\/II Clinical Trial","volume":"40","author":"Yilmaz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2022-157210","article-title":"Updated Results from a Phase I\/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3 -Mutated Acute Myeloid Leukemia","volume":"140","author":"Short","year":"2022","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2022-163084","article-title":"High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study","volume":"140","author":"Chua","year":"2022","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.HS9.0000844936.55710.7c","article-title":"P512: Preliminary results of ven-a-qui study: A phase 1-2 trial to assess the safety and efficacy of the combination of azacitidine or low-dose cytarabine with venetoclax and quizartinib in newly diagnosed","volume":"6","author":"Cano","year":"2022","journal-title":"HemaSphere"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e535260f","DOI":"10.1097\/01.HS9.0000968848.53526.0f","article-title":"P485: Azacitidine, venetoclax and gilteritinib for patients with newly diagnosed flt3-mutated acute myeloid leukemia: A subgroup analysis from a phase ii study","volume":"7","author":"Short","year":"2023","journal-title":"HemaSphere"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1182\/blood-2021-151648","article-title":"Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML)","volume":"138","author":"Abuasab","year":"2021","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-023-01437-1","article-title":"Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed\/Refractory AML: A Multicenter, Phase 2 Trial","volume":"16","author":"Jin","year":"2023","journal-title":"J. Hematol. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/21\/15849\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:22:39Z","timestamp":1788168159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/21\/15849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":133,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["ijms242115849"],"URL":"https:\/\/doi.org\/10.3390\/ijms242115849","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,31]]}}}